Although depression-associated elevation of TNF-α theoretically establishes a molecular foundation for cancer progression—through activation of multiple signaling pathways such as NF-κB, PI3K-AKT, and MAPK that promote inflammatory microenvironments, immune evasion, and apoptosis resistance—its direct clinical translatability faces substantial challenges. This evidence concerns the gene AKT1 and depressive symptom measurement.